Deerfield Management Company, L.P. (Series C) Delcath Systems, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $3.95 Billion
- Q1 2025
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Delcath Systems, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 813,106 shares of DCTH stock, worth $13.9 Million. This represents 0.26% of its overall portfolio holdings.
Number of Shares
813,106Holding current value
$13.9 Million% of portfolio
0.26%Shares
3 transactions
Others Institutions Holding DCTH
# of Institutions
100Shares Held
12.1MCall Options Held
79KPut Options Held
53.3K-
Vanguard Group Inc Valley Forge, PA1.39MShares$23.8 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA750KShares$12.8 Million2.59% of portfolio
-
Exodus Point Capital Management, LP New York, NY699KShares$12 Million0.09% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA557KShares$9.53 Million0.0% of portfolio
-
Gilder Gagnon Howe & CO LLC New York, NY539KShares$9.21 Million0.1% of portfolio
About DELCATH SYSTEMS, INC.
- Ticker DCTH
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 8,597,680
- Market Cap $147M
- Description
- Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling syste...